Company Profile

ElixinPharma was founded in 1999 to assist new and emerging pharmaceutical companies with their Chemistry, Manufacturing and Controls (CMC) needs. Over the years, we have built a reputation for providing high quality, highly strategic management of the complex CMC issues surrounding not only small molecules but also novel technologies such as oligonucleotides.

Our client base ranges from small venture-backed start-up companies to large multi-national pharmaceutical companies. Currently, over 90 % of our projects are in the area of oligonucleotide therapeutics, including antisense, aptamers, PEGylated aptamers, DNA duplex decoys, siRNA, and other complex oligonucleotides in a variety of formulations for parenteral, topical, intravitreal, pulmonary and oral delivery.

We are intimately familiar with the challenges faced by start-up companies with respect to meeting development milestones, partnering issues, regulatory interactions and cash flow management. We work with these companies on topics beyond the science, helping to manage the development programs in a staged manner to better utilize limited resources while minimizing overall risk to the program.

As larger pharma companies have entered this field through maturation of their internal programs or through licensing agreements with smaller companies, new challenges have emerged; CMC and regulatory teams must adapt their internal systems, usually geared towards small molecule therapeutics, to the unique requirements of oligonucleotides. We work with these teams to leverage their strengths while implementing innovative techniques to effectively manage the new programs.